This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exactech Announces Preliminary 2012 Sales Of $224.8 Million And 4th Quarter 2012 Sales Of $59.7 Million

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it expects to report revenue for the fourth quarter of 2012 of $59.7 million, an increase of 13% compared to $53.1 million for the fourth quarter of 2011 which will result in full year unaudited revenues of $224.8 million, compared to $205.4 million for 2011, a 9% increase. For the full year 2012, U.S. sales increased 9% to $145.6 million and international sales increased 9% to $79.2 million. During the fourth quarter, U.S. sales grew 13% to $38.3 million and international sales increased 13% during the quarter to $21.5 million.

Full year sales by product segment were as follows:

2012 Full Year

• Knee implant revenue increased 2% to $81.6 million

• Extremities implant revenue increased 30% to $52.1 million

• Hip implant revenues increased 21% to $40.9 million

• Biologic & spine segment revenues increased 1% to $24.5 million

• Other revenue decreased to $25.7 million from $27.4 million in 2011

Fourth quarter sales by product segment were as follows:

4 th Quarter 2012

• Knee implant revenue increased 4% to $20.9 million

• Extremities implant revenue increased 35% to $14.9 million

• Hip implant revenues increased 12% to $10.4 million

• Biologic & spine segment revenues increased 10% to $6.5 million

• Other revenue increased 4% to $7.0 million from $6.6 million.

Exactech will announce full results for the fourth quarter and year-end 2012 on Tuesday, February 26, 2013. The company will hold a conference call with CEO Dr. William Petty and key members of the management team on Wednesday, February 27 at 10:00 a.m. Eastern. Further details will be released at a later date.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs